The US Food and Drug Administration’s decision breathes new life into RNA-interference therapies. RNA-interference therapies were once left for dead but now the US Food and Drug Administration has approved patisiran.
No takes yet. Share an insight, caveat, or question.
Heidi K. Ledford (2018) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: